A patient with advanced renal impairment receives morphine and develops prolonged adverse opioid effects.
Which pharmacokinetic change best explains the increased risk?
A
Accumulation of morphine glucuronides
B
Reduced oral bioavailability of morphine
C
Increased plasma protein binding of morphine
D
Reduced morphine penetration into the brain
E
Increased elimination of morphine glucuronides